ClinicalTrials.gg
CompletedNCT03025022Updated May 10, 2017

A Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-JNJ-42847922 After a Single Oral Dose of 40 mg in Healthy Subjects

A Phase 1 interventional study of 14C-JNJ-42847922 40 mg in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-10.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Feb 2017, 9 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The objective of this study is to evaluate the absorption, distribution, metabolism, and excretion (ADME) of 14C-JNJ-42847922 in healthy subjects after a single oral dose of 40 milligram (mg) 14C-JNJ-42847922 containing maximally 100 MicroCurie. Safety and tolerability will also be assessed.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed an document indicating they (healthy participants) understand the purpose of and procedures required for the study and are willing to participate in the study
  • Willing to adhere to the prohibitions and restrictions specified in the protocol
  • Women may be eligible to participate if they are of non , which is defined as (a) : A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level (more than [>] 40 International Units Per Litre [IU/L] or milli-International Units per milliliter [mIU/mL]) in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal or hormonal replacement therapy, however in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient; OR (b) Permanently Sterile: Permanent sterilization methods include hysterectomy, bilateral salpingectomy, bilateral tubal occlusion/ligation procedures, and bilateral oophorectomy
  • (BMI; weight kilogram [kg]/height\^2 (meter [m]\^2)) between 18 and 30 kilogram per meter square (kg/m\^2) (inclusive), and body weight not less than 50 kg (kilogram)
  • Blood pressure (after the participant is supine for 5 minutes) between 90 and 140 millimeter of Merury (mmHg) systolic, inclusive, and no higher than 90 mmHg diastolic at screening and on Day -1
  • A 12-lead (ECG) consistent with normal cardiac conduction and function, including: Sinus rhythm, Pulse rate between 45 and 90 beats per minute (bpm), (QTc) interval less than and equal to (\<=) 450 millisecond (msec), QRS interval of \<110 msec, PR interval less than (\<) 200 msec. Morphology consistent with healthy cardiac conduction and function.
  • During the study and for a minimum of 1 spermatogenesis cycle (defined as approximately 90 days) after receiving the last dose of study drug, in addition to the user independent highly effective method of contraception, a man who is sexually active with a woman of childbearing potential must agree to use a barrier method of contraception (example [e.g.], condom with spermicidal foam/gel/film/cream/suppository) or must agree not to donate sperm, who is pregnant must use a condom.
  • Non-tobacco user (nicotine substances, including tobacco products (e.g., cigarettes, e-cigarettes, cigars, chewing tobacco, gum or patch) (current and for past 6 months prior to screening)

Exclusion criteria

Exclusion Criteria:

  • Exposure to significant radiation for professional or medical reasons except dental x-rays (example, serial x-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring) within 12 months prior to dosing. Exposure to X-rays of thorax and bone skeleton, (excluding spinal column) in the past 12 months
  • Participants cannot have participated in a radiolabelled drug study for 12 months prior to dosing
  • History of or current medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), syncope, hypotension, hypertension or vascular disorders, lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, hepatic or renal insufficiency ( below 60 milliLiter per minute (mL/min), kidney or urinary tract disturbances, thyroid disease, neurologic disease, significant psychiatric disorder, epilepsy, or fits of unexplained black-outs, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results
  • Has a history of within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, that in the opinion of the investigator, with concurrence with the Sponsor's Medical Monitor, is considered cured with minimal risk of recurrence)
  • Clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at screening or at admission to the study center as deemed appropriate by the investigator
  • Use of any prescription or nonprescription medication (including vitamins and herbal supplements), except for acetaminophen (325 milligram [mg]), within 14 days before the first dose of the study drug is scheduled until completion of the study
  • Received a known inhibitor of cytochrome P450 (CYP) 3A4 or CYP2C9 activity within 28 days or a period less than 5 times the drug's half life (t1/2), whichever is longer, before the dose of the study drug is scheduled until completion of the study
  • Received a known inducer of or CYP2C9 activity within 28 days before the dose of study drug is scheduled until completion of the study
  • Consumption of grapefruit products within 28 days before the first dose of the study drug is scheduled until completion of the study
  • Received an experimental drug or used an experimental medical device within 1 month or within a period less than 10 times the drug's half life (t1/2), whichever is longer, before the dose of the study drug is scheduled
  • History of drug or alcohol abuse according to (4th edition) (DSM-IV) criteria within 1 year before screening or positive test result(s) for alcohol, cotinine, and/or drugs of abuse (such as hallucinogens, barbiturates, opiates, opioids, cocaine, cannabinoids, amphetamines, and benzodiazepines) at screening and Day -1 of the treatment period
  • Known allergy to the study drug or any of the of the formulation
  • Donated blood or blood products or had substantial loss of blood (more than 500 milliLitre [mL]) within 3 months before the first administration of study drug or intention to donate blood or blood products during the study
  • If a man, who plans to father a child while enrolled in the study or for 3 months after receiving the last dose of study drug
  • Positive test for (HIV) 1 and 2 antibodies, surface antigen (HBsAg), or antibodies
  • Regular use of tobacco or nicotine containing products in the past 6 months, as determined by medical history or participant's verbal report
  • Positive test result(s) for nicotine at screening or Day -1 of the treatment period
  • Recent changes in bowel habits (frequency, consistency, and amount) and irregular defecation pattern (less than one defecation per day)
  • Preplanned surgery or procedures that would interfere with the conduct of the study
  • Employee of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator or employees of Johnson \& Johnson
  • Any participant who, in the opinion of the Investigator, should not participate in this study
  • Has suicidal ideation with some intent to act, as per Columbia Suicide Severity Rating Scale (C-SSRS)
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    14C-JNJ-42847922 40 miiligram (mg)

    Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 on Day 1.

    Drug: 14C-JNJ-42847922 40 mg

Interventions

  • Drug14C-JNJ-42847922 40 mg

    Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 containing maximally 100 MicroCurie as a 40 milliLitre (mL) solution.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    The Cmax is the maximum observed plasma concentration.

    Time frame: Predose (-0.5 h), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 32, 36, 48, 54, 60, and 72 hours postdose

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.

    Time frame: Predose (-0.5 h), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 32, 36, 48, 54, 60, and 72 hours postdose

  3. Time to Last Observed Quantifiable Concentration (T[last])

    The T(last) is the time to last observed quantifiable concentration.

    Time frame: Predose (-0.5 h), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 32, 36, 48, 54, 60, and 72 hours postdose

  4. Area Under the Curve From Time Zero to End of Dosing Interval (AUC[last])

    The AUC(last) is the measure of the plasma drug concentration from time zero to time of the last observed quantifiable concentration.

    Time frame: Predose (-0.5 h), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 32, 36, 48, 54, 60, and 72 hours postdose

  5. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])

    The AUC(infinity) is the area under the plasma concentration time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.

    Time frame: Predose (-0.5 h), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 32, 36, 48, 54, 60, and 72 hours postdose

  6. Percent of AUC(0-infinity) Extrapolated (%AUC_extrap)

    The %AUC_extrap is the percentage of AUC(0-infinity) accounted for by extrapolation. It is calculated as (AUC \[infinity\] minus \[-\] AUC\[last\])\*100/ AUC\[infinity\], where AUC\[infinity\] is area under the plasma concentration versus time curve from time zero to extrapolated infinite time and AUC(last) is area under the plasma concentration time-curve from zero to the last measured concentration.

    Time frame: Predose (-0.5 h), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 32, 36, 48, 54, 60, and 72 hours postdose

  7. Elimination Half-Life (t[1/2])

    The elimination half-life (t\[1/2\]) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).

    Time frame: Predose (-0.5 h), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 32, 36, 48, 54, 60, and 72 hours postdose

  8. Elimination Rate Constant (Lambda [z])

    Lambda(z) is first-order elimination rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.

    Time frame: Predose (-0.5 h), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 32, 36, 48, 54, 60, and 72 hours postdose

  9. Apparent Total Clearance (CL/F)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Predose (-0.5 h), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 32, 36, 48, 54, 60, and 72 hours postdose

  10. Apparent Volume of Distribution (Vd/F)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vd/F) is influenced by the fraction absorbed.

    Time frame: Predose (-0.5 h), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 32, 36, 48, 54, 60, and 72 hours postdose

  11. Amount of Drug Excreted in Urine (Ae)

    Ae refers to the total amount of drug excreted in urine.

    Time frame: Up to Day 14

  12. Percentage of Drug Excreted in Urine (%Ae)

    The %Ae is the percentage of drug dose excreted into the urine calculated as (Ae divided by dose)∗100.

    Time frame: Up to Day 14

  13. Renal Clearance (CLr)

    The CLr is the renal clearance of the drug, calculated as Ae/AUC(0-infinity).

    Time frame: Up to Day 14

  14. Amount of Drug Excreted in Feces (Fe)

    The Fe refers to the total amount of drug excreted in feces.

    Time frame: Up to Day 14

  15. Percentage of Drug Excreted in Feces (%Fe)

    The %Fe is the total amount excreted in feces, expressed as a percentage of the administered dose.

    Time frame: Up to Day 14

  16. Number of Participants With Adverse Events as a Measure of Safety and Tolerability

    Time frame: From Screening to End of study (Approximately up to 46 days)

07

Study locations

1 site
  • Madison, Wisconsin, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Feb 2017, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2017
First posted
Jan 19, 2017
StartActual
Jan 17, 2017
Primary completionActual
Feb 27, 2017
CompletionActual
Feb 27, 2017
Last update
May 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03025022
Responsible party
Sponsor
First posted
Jan 19, 2017
Start date
Jan 17, 2017
Primary completion
Feb 27, 2017
Completion
Feb 27, 2017
Last update
May 10, 2017

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion